Database analysis reports renal events with sodium-glucose cotransporter 2 inhibitors in type 2 diabetes and chronic kidney disease, indicating potential real-world protection.
To evaluate whether sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy is associated with a reduction of renal events compared with other glucose-lowering drugs (oGLDs) among Japanese people with type 2 diabetes (T2D) and grade 3 (G3) chronic kidney disease (CKD) in a real-world clinical practice setting.
No takes yet. Share an insight, caveat, or question.
Iijima et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: